SSAs bind to somatostatin receptors, inhibiting secretion of growth hormone. This activity is also associated with undesirable inhibition of other endocrine hormones (eg, insulin, glucagon) in locations outside the pituitary.
We believe that COR-005 may offer an improved safety and efficacy profile—compared with current SSAs—because of its differentiated activation of somatostatin receptor subtypes. COR-005 has received orphan drug designation for acromegaly in the US and EU.
COR-005 (veldoreotide) is currently being optimized for sustained release and subcutaneous delivery.
In short-term Phase 1 and 2 studies in healthy volunteers and untreated patients with acromegaly, respectively, the effects of subcutaneously administered COR-005 on stimulated or basal growth hormone and postprandial glucose and insulin secretion were compared with those of subcutaneous injections of immediate-release octreotide. The findings suggest that COR-005 has similar ability as octreotide to suppress growth hormone but has reduced propensity to inhibit postprandial insulin.1,2
Findings from these studies suggest that COR-005 warrants further investigation as a treatment for acromegaly.
No serious adverse events were observed, and mostly mild adverse events typical for SSAs such as injection site reactions and gastrointestinal side effects were reported. There was no evidence that COR-005 adversely affects the liver, kidneys, or other organ systems, including the cardiovascular system.
The safety and efficacy of COR-005 for treatment of acromegaly have not been established.